Literature DB >> 25757092

Luotonin-A based quinazolinones cause apoptosis and senescence via HDAC inhibition and activation of tumor suppressor proteins in HeLa cells.

Ramineni Venkatesh1, M Janaki Ramaiah2, Hanmant K Gaikwad1, Sridhara Janardhan3, Rajashaker Bantu1, Lingaiah Nagarapu4, G Narahari Sastry3, A Raksha Ganesh2, Manikapal Bhadra2.   

Abstract

A series of novel quinazolinone hybrids were synthesized by employing click chemistry and evaluated for anti-proliferative activities against MCF-7, HeLa and K562 cell lines. Among these cell lines, HeLa cells were found to respond effectively to these quinazolinone hybrids with IC50 values ranging from 5.94 to 16.45 μM. Some of the hybrids (4q, 4r, 4e, 4k, 4t, 4w) with promising anti-cancer activity were further investigated for their effects on the cell cycle distribution. FACS analysis revealed the G1 cell cycle arrest nature of these hybrids. Further to assess the senescence inducing ability of these compounds, a senescence associated β-gal assay was performed. The senescence inducing nature of these compounds was supported by the effect of hybrid (4q) on p16 promoter activity, the marker for senescence. Moreover, cells treated with most effective compound (4q) show up-regulation of p53, p21 and down-regulation of HDAC-1, HDAC-2, HDAC-5 and EZH2 mRNA levels. Docking results suggest that, the triazole nitrogen showed Zn(+2) mediated interactions with the histidine residue of HDACs.
Copyright © 2015 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Click chemistry; Docking studies; HDACs; Quinazolinone hybrids; Senescence

Mesh:

Substances:

Year:  2015        PMID: 25757092     DOI: 10.1016/j.ejmech.2015.02.057

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  5 in total

Review 1.  Recent advances in the pharmacological diversification of quinazoline/quinazolinone hybrids.

Authors:  Prashant S Auti; Ginson George; Atish T Paul
Journal:  RSC Adv       Date:  2020-11-12       Impact factor: 4.036

2.  Synthesis and anticancer activity of novel quinazolinone-based rhodanines.

Authors:  Sherihan El-Sayed; Kamel Metwally; Abdalla A El-Shanawani; Lobna M Abdel-Aziz; Harris Pratsinis; Dimitris Kletsas
Journal:  Chem Cent J       Date:  2017-10-13       Impact factor: 4.215

Review 3.  From molecular promise to preclinical results: HDAC inhibitors in the race for healthy aging drugs.

Authors:  Rebecca L McIntyre; Eileen G Daniels; Marte Molenaars; Riekelt H Houtkooper; Georges E Janssens
Journal:  EMBO Mol Med       Date:  2019-08-01       Impact factor: 12.137

Review 4.  Histone Deacetylase Inhibitors as Therapeutic Interventions on Cervical Cancer Induced by Human Papillomavirus.

Authors:  Natália Lourenço de Freitas; Maria Gabriela Deberaldini; Diana Gomes; Aline Renata Pavan; Ângela Sousa; Jean Leandro Dos Santos; Christiane P Soares
Journal:  Front Cell Dev Biol       Date:  2021-01-28

Review 5.  Insights Into the Function and Clinical Application of HDAC5 in Cancer Management.

Authors:  Jun Yang; Chaoju Gong; Qinjian Ke; Zejun Fang; Xiaowen Chen; Ming Ye; Xi Xu
Journal:  Front Oncol       Date:  2021-06-10       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.